…
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth for the development of AI-powered breast cancer screening solutions. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
GE HealthCare Technologies supplies medical imaging, monitoring, diagnostics, imaging agents, clinical software and related services to hospitals and outpatient centers worldwide. Long-term growth could be driven by ageing populations, rising demand for diagnostics, recurring service revenue from a large installed base and adoption of digital/AI-enabled workflows, and the company’s scale may support relatively stable cash flows and product upgrades.
Key risks include strong competition, sensitivity to healthcare capital spending and reimbursement, regulatory and approval hurdles, and execution or supply-chain issues that could pressure margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 2768.00M | 2581.00M | 2361.00M | 2512.00M | 2875.00M |
| Minority interest | -70.00M | -57.00M | -46.00M | -51.00M | -46.00M |
| Net income | 2084.00M | 1993.00M | 3104.00M | 1916.00M | 2247.00M |
| Selling general administrative | 4150.00M | 4269.00M | 4282.00M | 3631.00M | 3563.00M |
| Gross profit | 8247.00M | 8205.00M | 7922.00M | 7179.00M | 7174.00M |
| Reconciled depreciation | 578.00M | 580.00M | 610.00M | 633.00M | 625.00M |
| Ebit | 3207.00M | 3086.00M | 2435.00M | 2522.00M | 2795.00M |
| Ebitda | 3785.00M | 3666.00M | 2435.00M | 3222.00M | 3540.00M |
| Depreciation and amortization | 578.00M | 580.00M | 610.00M | 700.00M | 745.00M |
| Operating income | 2762.00M | 2625.00M | 2435.00M | 2522.00M | 2795.00M |
| Other operating expenses | 17863.00M | 17047.00M | 17117.00M | 15819.00M | 14790.00M |
| Interest expense | 450.00M | 505.00M | 542.00M | 77.00M | 40.00M |
| Tax provision | 614.00M | 531.00M | 743.00M | 563.00M | 600.00M |
| Interest income | 41.00M | - | 26.00M | - | 34.00M |
| Net interest income | -399.00M | -505.00M | -516.00M | -77.00M | -6.00M |
| Income tax expense | 614.00M | 531.00M | -743.00M | 563.00M | 600.00M |
| Total revenue | 20625.00M | 19672.00M | 19552.00M | 18341.00M | 17585.00M |
| Total operating expenses | 5485.00M | 5580.00M | 5487.00M | 4657.00M | 4379.00M |
| Cost of revenue | 12378.00M | 11467.00M | 11630.00M | 11162.00M | 10411.00M |
| Total other income expense net | 6.00M | -44.00M | -74.00M | -10.00M | 80.00M |
| Discontinued operations | - | - | - | 18.00M | 18.00M |
| Net income from continuing ops | 2154.00M | 2050.00M | 1618.00M | 1949.00M | 2275.00M |
| Net income applicable to common shares | - | - | - | 1916.00M | 2247.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 36906.00M | 33089.00M | 32454.00M | 27539.00M | 26308.00M |
| Intangible assets | 1130.00M | 1078.00M | 1253.00M | 1520.00M | 1847.00M |
| Other current assets | 81.00M | 311.00M | 61.00M | 417.00M | 88.00M |
| Total liab | 26307.00M | 24436.00M | 25144.00M | 18177.00M | 9632.00M |
| Total stockholder equity | 10379.00M | 8447.00M | 7133.00M | 9357.00M | 16655.00M |
| Deferred long term liab | - | - | - | 82.00M | 77.00M |
| Other current liab | 5347.00M | 2692.00M | 3000.00M | 2336.00M | 2247.00M |
| Common stock | 5.00M | 5.00M | 5.00M | 11235.00M | 17692.00M |
| Capital stock | 5.00M | 5.00M | 5.00M | 0.00M | 17692.00M |
| Retained earnings | 5281.00M | 3262.00M | 1326.00M | - | - |
| Other liab | - | - | - | 2240.00M | 2324.00M |
| Good will | 13489.00M | 13136.00M | 12936.00M | 12813.00M | 12892.00M |
| Other assets | 4003.00M | 1509.00M | 3302.00M | 2534.00M | 1993.00M |
| Cash | 4512.00M | 2890.00M | 2494.00M | 1445.00M | 554.00M |
| Total current liabilities | 9105.00M | 9553.00M | 8981.00M | 7191.00M | 6761.00M |
| Current deferred revenue | - | 1943.00M | 1918.00M | 1896.00M | 1864.00M |
| Net debt | 5491.00M | 6486.00M | 7369.00M | 6804.00M | -117.00M |
| Short term debt | 508.00M | 1617.00M | 1116.00M | 15.00M | 110.00M |
| Short long term debt | 508.00M | 1502.00M | 1006.00M | 15.00M | 6.00M |
| Short long term debt total | 10003.00M | 9376.00M | 9863.00M | 8249.00M | 437.00M |
| Other stockholder equity | 6481.00M | 6559.00M | 6493.00M | 18801.00M | -1037.00M |
| Property plant equipment | - | - | - | 2314.00M | 2235.00M |
| Total current assets | 10701.00M | 9516.00M | 9410.00M | 8318.00M | 7000.00M |
| Long term investments | 351.00M | 373.00M | 357.00M | 322.00M | 341.00M |
| Net tangible assets | - | - | - | -4976.00M | 1916.00M |
| Short term investments | - | 15.00M | - | - | - |
| Net receivables | 3955.00M | 4376.00M | 4254.00M | 4301.00M | 3791.00M |
| Long term debt | 9495.00M | 7449.00M | 8436.00M | 8234.00M | 31.00M |
| Inventory | 2234.00M | 1939.00M | 1960.00M | 2155.00M | 1946.00M |
| Accounts payable | 3250.00M | 3022.00M | 2947.00M | 2944.00M | 2540.00M |
| Accumulated other comprehensive income | -1388.00M | -1379.00M | -691.00M | -1878.00M | -1037.00M |
| Non currrent assets other | 233.00M | 1531.00M | 1524.00M | 702.00M | 286.00M |
| Non current assets total | 22202.00M | 23573.00M | 23044.00M | 19221.00M | 19308.00M |
| Capital lease obligations | 460.00M | 425.00M | 421.00M | 386.00M | 400.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -118.00M | -914.00M | -558.00M | -398.00M | -1761.00M |
| Change to liabilities | - | - | - | 619.00M | 242.00M |
| Total cashflows from investing activities | -1047.00M | -914.00M | -558.00M | -398.00M | -1761.00M |
| Net borrowings | 968.00M | -423.00M | 1139.00M | 8204.00M | -12.00M |
| Total cash from financing activities | 617.00M | -573.00M | -478.00M | -822.00M | -263.00M |
| Change to operating activities | - | - | - | -81.00M | 251.00M |
| Net income | 2154.00M | 2050.00M | 1618.00M | 1949.00M | 2275.00M |
| Change in cash | 1622.00M | 387.00M | 1055.00M | 890.00M | -451.00M |
| Begin period cash flow | 2893.00M | 2506.00M | 1451.00M | 561.00M | 1012.00M |
| End period cash flow | 4515.00M | 2893.00M | 2506.00M | 1451.00M | 561.00M |
| Total cash from operating activities | 1988.00M | 1951.00M | 2101.00M | 2113.00M | 1607.00M |
| Depreciation | 578.00M | 580.00M | 610.00M | 633.00M | 625.00M |
| Other cashflows from investing activities | -447.00M | -160.00M | 24.00M | -92.00M | -47.00M |
| Dividends paid | 64.00M | 55.00M | 41.00M | - | - |
| Change to inventory | -142.00M | -81.00M | 111.00M | -402.00M | -435.00M |
| Change to account receivables | -216.00M | -150.00M | -171.00M | -231.00M | -1336.00M |
| Sale purchase of stock | -200.00M | 0.00M | 0.00M | - | - |
| Other cashflows from financing activities | -123.00M | -128.00M | -1576.00M | -819.00M | -246.00M |
| Change to netincome | - | - | - | -341.00M | 13.00M |
| Capital expenditures | 482.00M | 401.00M | 387.00M | 310.00M | 248.00M |
| Change in working capital | -357.00M | -59.00M | 22.00M | -256.00M | -1370.00M |
| Stock based compensation | 130.00M | 125.00M | 114.00M | - | - |
| Other non cash items | -517.00M | -1276.00M | -1006.00M | -776.00M | -523.00M |
| Free cash flow | 1506.00M | 1550.00M | 1714.00M | 1803.00M | 1359.00M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GEHC GE HealthCare Technologies Inc. |
1.09 1.32% |
83.47 | 15.88 | 14.62 | 1.60 | 3.26 | 1.93 | 10.51 |
| ABT Abbott Laboratories |
0.46 0.42% |
110.39 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.14 0.14% |
101.66 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
1.50 0.46% |
327.37 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
0.56 1.12% |
50.41 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth for the development of AI-powered breast cancer screening solutions. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
500 West Monroe Street, Chicago, IL, United States, 60661
833 735 1139
54000
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter J. Arduini | President, CEO & Director | 1965 |
| Mr. James K. Saccaro | VP & CFO | 1973 |
| Dr. Taha Kass-Hout M.D., M.S. | Chief Science & Technology Officer | 1972 |
| Mr. Frank R. Jimenez Esq. | VP, General Counsel & Corporate Secretary | 1965 |
| Mr. Jan Makela | President & CEO of Imaging | 1969 |
| Mr. George Andrew Newcomb | Controller & Chief Accounting Officer | 1967 |
| Mr. Jahid Khandaker | Chief Information Officer | NA |
| Ms. Carolynne Borders | Chief Investor Relations Officer | NA |
| Ms. Rana Strellis | Chief Corporate Marketing & Communications Officer | NA |
| Mr. Thomas J. Westrick | President & CEO of Patient Care Solutions | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.